Explain this page
Arphra AIPlain-English read on Insulet Corporation’s valuation06-03today
- Insulet Corporation (PODD) Discusses Recent Product Recalls and Physician Community Response at ADA Meeting Transcript2d
- Why Insulet (PODD) is a Top Momentum Stock for the Long-Term3d
- Insulet Corporation Valuation Pressure Has Dropped Enough (Upgrade)6d
- Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care9d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$523.34
+249.59% vs spot
Recommendation
Strong Buy
15 of 16 methods
Method spread
4bull10bear
±5% threshold
Analyst PT consensus: $339.00 (+126.45%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.34% | -5.85% | +1.52% | -31.91% | -48.65% | -47.33% | -51.17% | -47.86% | -46.10% | +402.69% | +837.97% |
Insider · 30d
History →Bought
$1.83M
3 txns
Sold
$3.99M
7 txns
Net flow
−$2.16M
Aftermarket
LiveLast trade
$150.66
103 sh
Bid
$149.70
3 sh
Ask
$152.05
3 sh
Spread
$2.350
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $783.8M | $101.6M | $1.44 |
| Q3 Sep 2025 | $706.3M | $87.6M | $1.24 |
| Q2 Jun 2025 | $649.1M | $22.5M | $0.32 |
| Q1 Mar 2025 | $569M | $35.4M | $0.50 |
| Q4 Dec 2024 | $597.5M | $100.7M | $1.39 |
| Q3 Sep 2024 | $543.9M | $77.5M | $1.08 |
Sector & industry today
LiveSectors
- Utilities+2.58%
- Energy+1.31%
- Basic Materials+0.81%
- Consumer Defensive+0.72%
- Technology+0.67%
- Real Estate+0.47%
- Financial Services+0.33%
- Industrials+0.06%
- Consumer Cyclical-0.34%
- Communication Services-0.77%
- Healthcare-1.62%
Top industries (issuer's industry highlighted)
- Medical - Devices+0.05%
- Broadcasting-4.06%
- Coal+3.67%
- Renewable Utilities+3.61%
- Silver+3.21%
- Computer Hardware+2.54%
- Medical - Equipment & Services-2.31%
- Oil & Gas Energy+2.30%
- Auto - Dealerships-2.28%
- Copper+2.24%
- Drug Manufacturers - General-2.21%
- Medical - Healthcare Information Services-2.20%
Analyst view
DB · price_targets + analyst_gradesConsensus target
$339.00
+126.45% upside
Low
$220.00
Median
$330.00
High
$435.00
Recent actions
0 ↑0 ↓8 hold
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
- Dec 01, 2025
News
DB · news_items- Insulet Corporation (PODD) Discusses Recent Product Recalls and Physician Community Response at ADA Meeting Transcriptseekingalpha.com·Jun 12, 2026
- Why Insulet (PODD) is a Top Momentum Stock for the Long-Termzacks.com·Jun 11, 2026
- Insulet Corporation Valuation Pressure Has Dropped Enough (Upgrade)seekingalpha.com·Jun 08, 2026
- Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Caregurufocus.com·Jun 06, 2026
- Why Is Insulet (PODD) Down 8.7% Since Last Earnings Report?zacks.com·Jun 05, 2026
- Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessionsbusinesswire.com·Jun 04, 2026
- Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessionsbusinesswire.com·Jun 04, 2026
- Insulet Corporation (PODD) Presents at 46th Annual William Blair Growth Stock Conference Transcriptseekingalpha.com·Jun 03, 2026
Recent analyst activity
DB- Jun 11, 2026PT$219.00Insulet price target lowered to $219 from $250 at TruistUBS
- Jun 11, 2026PT$219.00Insulet Corporation (PODD) PT Lowered to $219 at Truist SecuritiesTruist Financial
- Jun 08, 2026PT$216.00Insulet price target lowered to $216 from $263 at Raymond JamesRaymond James
Peers
Total assets
$3.19B
Total debt
$1.05B
Cash & equiv
$716.1M
Operating CF
$569.3M
Free cash flow
$377.7M
Buybacks
-$59.6M
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
MINOGUE MICHAEL R director | Buy | 2,030 | $499.85K | Feb 25, 2026 |
McEvoy Ashley director, officer: President and CEO | Buy | 4,300 | $1.03M | Feb 20, 2026 |
Frederick Wayne A.I. director | Sell | 1,851 | $542.51K | Dec 15, 2025 |
STONESIFER TIMOTHY C. director | Buy | 962 | $299.88K | Dec 05, 2025 |
Singh Prem officer: SVP, Global Operations | Sell | 687 | $238.73K | Sep 08, 2025 |
Cousin Laetitia officer: SVP, Reg, Quality & Compliance | Sell | 797 | $278K | Sep 08, 2025 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $2.71B | $473.8M | $247.1M | $3.48 | +9.12% |
| FY 2024 | $2.07B | $308.9M | $418.3M | $5.78 | +20.19% |
| FY 2023 | $1.7B | $220M | $206.3M | $2.94 | +12.16% |
| FY 2022 | $1.31B | $37.6M | $4.6M | $0.07 | +0.35% |
| FY 2021 | $1.1B | $126M | $16.8M | $0.25 | +1.53% |